Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Sci Rep ; 14(1): 10983, 2024 05 14.
Article in English | MEDLINE | ID: mdl-38744869

ABSTRACT

Parkinson's disease (PD) is a complex neurodegenerative disorder without a cure. The onset of PD symptoms corresponds to 50% loss of midbrain dopaminergic (mDA) neurons, limiting early-stage understanding of PD. To shed light on early PD development, we study time series scRNA-seq datasets of mDA neurons obtained from patient-derived induced pluripotent stem cell differentiation. We develop a new data integration method based on Non-negative Matrix Tri-Factorization that integrates these datasets with molecular interaction networks, producing condition-specific "gene embeddings". By mining these embeddings, we predict 193 PD-related genes that are largely supported (49.7%) in the literature and are specific to the investigated PINK1 mutation. Enrichment analysis in Kyoto Encyclopedia of Genes and Genomes pathways highlights 10 PD-related molecular mechanisms perturbed during early PD development. Finally, investigating the top 20 prioritized genes reveals 12 previously unrecognized genes associated with PD that represent interesting drug targets.


Subject(s)
Dopaminergic Neurons , Parkinson Disease , Parkinson Disease/genetics , Parkinson Disease/pathology , Humans , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/pathology , RNA-Seq/methods , Induced Pluripotent Stem Cells/metabolism , Mesencephalon/metabolism , Mesencephalon/pathology , Gene Regulatory Networks , Mutation , Cell Differentiation/genetics , Multiomics , Single-Cell Gene Expression Analysis
2.
Healthcare (Basel) ; 10(9)2022 Sep 07.
Article in English | MEDLINE | ID: mdl-36141325

ABSTRACT

It has been hypothesized since the 1960s that the etiology of schizophrenia is linked to dopamine. In the intervening 60 years, sophisticated brain imaging techniques, genetic/epigenetic advances, and new experimental animal models of schizophrenia have transformed schizophrenia research. The disease is now conceptualized as a heterogeneous neurodevelopmental disorder expressed phenotypically in four symptom domains: positive, negative, cognitive, and affective. The aim of this paper is threefold: (a) to review recent research into schizophrenia etiology, (b) to review papers that elicited subjective evidence from patients as to triggers and repressors of symptoms such as auditory hallucinations or paranoid thoughts, and (c) to address the potential role of dopamine in schizophrenia in general and, in particular, in the fluctuations in schizophrenia symptoms. The review also includes new discoveries in schizophrenia research, pointing to the involvement of both striatal neurons and glia, signaling pathway convergence, and the role of stress. It also addresses potential therapeutic implications. We conclude with the hope that this paper opens up novel avenues of research and new possibilities for treatment.

3.
Stem Cell Res ; 61: 102765, 2022 05.
Article in English | MEDLINE | ID: mdl-35378365

ABSTRACT

Mutations in PINK1 and Parkin are two of the main causes of recessive early-onset Parkinson's disease (PD). We generated human induced pluripotent stem cells (hiPSCs) from fibroblasts of a 64-year-old male patient with a homozygous ILE368ASN mutation in PINK1, who experienced disease onset at 33 years, and from fibroblasts of a 61-year-old female patient heterozygous for the R275W mutation in Parkin, who experienced disease onset at 44 years. Array comparative genomic hybridization (aCGH) determined genotypic variation in each line. The cell lines were successfully used to generate midbrain dopaminergic neurons, the neuron type primarily affected in PD.


Subject(s)
Induced Pluripotent Stem Cells , Parkinson Disease , Comparative Genomic Hybridization , Dopaminergic Neurons/metabolism , Female , Fibroblasts/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Male , Middle Aged , Mutation/genetics , Parkinson Disease/genetics , Parkinson Disease/metabolism , Protein Kinases/genetics , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolism
4.
Commun Biol ; 5(1): 49, 2022 01 13.
Article in English | MEDLINE | ID: mdl-35027645

ABSTRACT

Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder, characterized by the loss of dopaminergic neurons (mDA) in the midbrain. The underlying mechanisms are only partly understood and there is no treatment to reverse PD progression. Here, we investigated the disease mechanism using mDA neurons differentiated from human induced pluripotent stem cells (hiPSCs) carrying the ILE368ASN mutation within the PINK1 gene, which is strongly associated with PD. Single-cell RNA sequencing (RNAseq) and gene expression analysis of a PINK1-ILE368ASN and a control cell line identified genes differentially expressed during mDA neuron differentiation. Network analysis revealed that these genes form a core network, members of which interact with all known 19 protein-coding Parkinson's disease-associated genes. This core network encompasses key PD-associated pathways, including ubiquitination, mitochondrial function, protein processing, RNA metabolism, and vesicular transport. Proteomics analysis showed a consistent alteration in proteins of dopamine metabolism, indicating a defect of dopaminergic metabolism in PINK1-ILE368ASN neurons. Our findings suggest the existence of a network onto which pathways associated with PD pathology converge, and offers an inclusive interpretation of the phenotypic heterogeneity of PD.


Subject(s)
Cell Differentiation/genetics , Induced Pluripotent Stem Cells/physiology , Mutation , Parkinson Disease/physiopathology , Protein Kinases/genetics , Transcriptome , Gene Expression Profiling , Humans , Neurogenesis , Parkinson Disease/genetics , Sequence Analysis, RNA , Single-Cell Analysis
5.
Stem Cell Res ; 57: 102569, 2021 Oct 12.
Article in English | MEDLINE | ID: mdl-34736041

ABSTRACT

Mutations in the LRRK2 gene are known to mediate predisposition to Parkinson disease. Fibroblasts heterozygous for the G2019S LRRK2 mutation were obtained from a 53-year-old male patient with disease onset at 34 years (LCSBi005, ND29542), and from a 63-year-old male patient with disease onset at 56 years (LCSBi006, ND34267). Induced pluripotent stem cell (iPSC) clones were generated for each cell line using Sendai virus. The absence of chromosomal defects was confirmed using array comparative genomic hybridization. The cell lines express pluripotency markers and have the ability to differentiate into all three germ layers.

6.
Stem Cell Res ; 57: 102600, 2021 Nov 22.
Article in English | MEDLINE | ID: mdl-34826737

ABSTRACT

Mutations in the SNCA (α-synuclein, PARK1) gene significantly contribute to Parkinson's disease and SNCA inclusions are strongly associated with PD. Fibroblasts from a 51-year-old female patient with disease onset at 39 years, carrying the A53T SNCA mutation (LCSBi003, ND40996), and fibroblasts with a triplication of the SNCA gene obtained from a 55-year-old female patient with disease onset at 52 years (LCSBi007, ND27760), were reprogrammed into human induced pluripotent stem cells (iPSCs) using Sendai virus. The presence of other genetic variants was determined using array comparative genomic hybridization. Presence of SNCA triplication was confirmed by FISH analysis.

7.
Int J Dev Neurosci ; 31(3): 189-95, 2013 May.
Article in English | MEDLINE | ID: mdl-23313435

ABSTRACT

The goal of this study was to determine whether two stressors commonly used to model aspects of neuropsychiatric disease in rats have an additive effect on striatal dopamine type 2 receptor (D2R) expression, a key player in the etiology of neuropsychiatric disease. Animals subjected to early postnatal stress show alterations in function of the dopaminergic system thought to be mediated by stress-induced glucocorticoid release. Subsequent stress during puberty is known to further impact the dopaminergic system and result in dopaminergic hyperactivity analogous to schizophrenia. We exposed rats to maternal deprivation (MD) during the second postnatal week, a time of active striatal development. A subset of these animals were then subjected to pubertal stress induced by immobilization. Both procedures are know to induce glucocorticoid release. At the conclusion of the MD protocol, we observed upregulation in the expression of D2R and of dopamine- and cAMP-regulated phosphoprotein 32-KD (DARPP-32; PPP1R1B), but not of D1R, calcium/calmodulin-dependent protein kinase II beta (CaMKIIß), CaMKIIα or neurokinin B (NKB). Animals exposed to pubertal stress showed upregulation in expression of both D2R and CaMKIIß. Furthermore, rats previously exposed to MD showed a much greater upregulation in CaMKIIß expression, than animals only exposed to pubertal stress. These results support the two-hit hypothesis, indicating that such stressors have an additive effect. The main targets appear to be the D2R and the CaMKIIß, the latter being an important member of the DR signalling pathway, both of which are associated with schizophrenia.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Corpus Striatum/metabolism , Maternal Deprivation , Receptors, Dopamine D2/metabolism , Stress, Physiological/physiology , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Female , Gene Expression , Male , Neurons/metabolism , Phosphorylation , Rats , Receptors, Dopamine D2/genetics , Restraint, Physical , Up-Regulation
8.
Synapse ; 67(4): 179-88, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23184870

ABSTRACT

Because abnormal development of striatal neurons is thought to be the part of pathology underlying major psychiatric illnesses, we studied the expression pattern of genes involved in striatal development and of genes comprising key striatal-specific pathways, during an active striatal maturation period, the first two postnatal weeks in rat. This period parallels human striatal development during the second trimester, when prenatal stress is though to lead to increased risk for neuropsychiatric disorders. To identify genes involved in this developmental process, we used subtractive hybridization, followed by quantitative real-time PCR, which allowed us to characterize the developmental expression of over 60 genes, many not previously known to play a role in neuromaturation. Of these 12 were novel transcripts, which did not match known genes, but which showed strict developmental expression and may play a role in striatal neurodevelopment. An additional 89 genes were identified as strong candidates for involvement in this neurodevelopmental process. We show that during the first two postnatal weeks in rat, an early gene expression network, still lacking key striatal-specific signaling pathways, is downregulated and replaced by a mature gene expression network, containing key striatal-specific genes including the dopamine D1 and D2 receptors, conferring to these neurons their functional identity. Therefore, before this developmental switch, striatal neurons lack many of their key phenotypic characteristics. This maturation process is followed by a striking rise in expression of myelination genes, indicating a striatal-specific myelination event. Such strictly controlled developmental program has the potential to be a point of susceptibility to disruption by external factors. Indeed, this period is known to be a susceptibility period in both humans and rats.


Subject(s)
Gene Expression Regulation, Developmental/physiology , Myelin Sheath/metabolism , Neostriatum/growth & development , Animals , GABAergic Neurons/metabolism , Gene Expression Profiling , Gene Regulatory Networks , Models, Animal , Neostriatum/embryology , Neostriatum/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D1/genetics , Receptors, Dopamine D1/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D2/metabolism , Schizophrenia/genetics , Synaptic Transmission/genetics
9.
Schizophr Res ; 124(1-3): e1-62, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20934307

ABSTRACT

The 2nd Schizophrenia International Research Society Conference, was held in Florence, Italy, April 10-15, 2010. Student travel awardees served as rapporteurs of each oral session and focused their summaries on the most significant findings that emerged from each session and the discussions that followed. The following report is a composite of these reviews. It is hoped that it will provide an overview for those who were present, but could not participate in all sessions, and those who did not have the opportunity to attend, but who would be interested in an update on current investigations ongoing in the field of schizophrenia research.


Subject(s)
Brain/pathology , Cognition , Schizophrenia , Schizophrenic Psychology , Animals , Disease Models, Animal , Humans , International Agencies , Schizophrenia/diagnosis , Schizophrenia/genetics , Schizophrenia/pathology , Schizophrenia/therapy , Societies, Scientific
10.
Int J Neurosci ; 120(11): 691-7, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20942582

ABSTRACT

Dopamine D2 receptors exist in both low- and high-affinity states (D2(High)), the latter being the functionally relevant state. Cocaine self-administration produces an increase in D2(High), a phenomenon that could explain why cocaine administration results in hypersensitivity to dopamine, even though drug addicts were found to have a decreased number of striatal dopamine D2 receptors. As nicotine acts through the same mesocortical dopaminergic signaling pathways as other stimulant drugs, which are known to increase the levels of D2(High), we hypothesized that nicotine exposure could produce an increase in D2(High) levels. We determined D2(High) levels in rats after nicotine administration (1.5 mg/kg/day; 14 days), in rats voluntarily self-administering nicotine using an intravenous self-administration (IVSA) protocol (mean dose 0.5 mg/kg/day; 14 days), as well as after a prolonged withdrawal. An increase in the levels of D2(High) was found in rats who had nicotine administered at a uniform dose, as well as in rats who self-administered nicotine via IVSA, but these changes appear to normalize over time, as indicated by lower D2(High) levels in rats after a prolonged withdrawal period. We suggest that nicotine-induced elevation in D2(High) levels could be participating in hypersensitivity to dopamine following nicotine exposure.


Subject(s)
Nicotine/administration & dosage , Nicotine/adverse effects , Receptors, Dopamine D2/metabolism , Substance Withdrawal Syndrome/metabolism , Animals , Behavior, Animal/drug effects , Corpus Striatum/drug effects , Corpus Striatum/physiology , Domperidone/chemical synthesis , Dopamine/metabolism , Humans , Male , Rats , Rats, Long-Evans , Self Administration , Tritium , Up-Regulation/drug effects
11.
Ann Hum Genet ; 74(4): 291-8, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20456319

ABSTRACT

Emerging evidence indicates that the DRD1-BDNF-DRD3 cluster plays an important role in nicotine addiction. We have performed an association analysis of 42 SNPs within these genes with cigarette consumption in a group of 341 schizophrenia patients. The ACCG haplotype consisting of four BDNF markers (Val66Met (rs6265), rs11030104, rs2049045 and rs7103411) showed an association with the risk of smoking (p = 0.0002). Both DRD1 markers tested (rs4532 and rs686) and the DRD3 marker (rs1025398) showed association with quantity of tobacco smoked (p = 0.01, 0.005 and 0.002, respectively). Our findings are preliminary; however, they support the involvement of the DRD1, BDNF and DRD3 genes in smoking behaviour.


Subject(s)
Brain-Derived Neurotrophic Factor/genetics , Polymorphism, Single Nucleotide , Receptors, Dopamine D1/genetics , Receptors, Dopamine D3/genetics , Schizophrenia/genetics , Smoking/genetics , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Risk
12.
Synapse ; 64(10): 794-800, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20336626

ABSTRACT

The cerebral frontal cortex of patients who had schizophrenia shows elevated levels of RNA for calcium/calmodulin-dependent protein kinase II beta (CaMKIIbeta). In addition, recent research shows that animal models for schizophrenia, such as amphetamine-sensitized rats, consistently show elevated levels of D2 receptors in their high-affinity state (D2(High)), the major target for antipsychotic medication. The present study was done, therefore, to examine whether an alteration in the levels of CaMKIIbeta could lead to altered levels of D2(High) receptors. We found that the CaMKII inhibitor, KN-93, markedly reduced D2(High) states in rat striatum. In addition, we studied heterozygous CaMKIIalpha knock-out mice that show features analogous to schizophrenia. The striata of these mice revealed a 2.8-fold increase in D2(High) receptors. In frontal cortex of the heterozygous CaMKIIalpha knock-out mice, CaMKIIalpha mRNA levels were reduced by 50%, while CaMKIIbeta mRNA levels were unaltered. In striatum, CaMKIIbeta mRNA levels were increased by 29%, suggesting the presence of a new CaMKIIbeta regulatory pathway not previously described. The elevated levels of CaMKIIbeta mRNA in the striatum suggest that this enzyme may increase D2(High) in animals and possibly in schizophrenia itself.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinase Type 2/deficiency , Gene Expression Regulation/genetics , Hyperkinesis/etiology , Receptors, Dopamine D2/metabolism , Schizophrenia , Animals , Benzylamines/pharmacology , Calcium-Calmodulin-Dependent Protein Kinase Type 2/genetics , Calcium-Calmodulin-Dependent Protein Kinase Type 2/metabolism , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Disease Models, Animal , Domperidone/metabolism , Enzyme Inhibitors/pharmacology , Gene Expression Regulation/drug effects , Hyperkinesis/genetics , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , RNA, Messenger/metabolism , Rats , Schizophrenia/complications , Schizophrenia/genetics , Schizophrenia/metabolism , Sulfonamides/pharmacology , Tritium/metabolism
13.
Psychiatr Genet ; 20(1): 39-43, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20010315

ABSTRACT

Recent evidence has identified the NR4A1 (NUR77, NGFI-B) gene as a strong candidate for involvement in tardive dyskinesia (TD). We have investigated the association of six single nucleotide polymorphisms within the NR4A family of genes with TD in a sample of 171 patients with schizophrenia of Caucasian descent. The NR4A1 single nucleotide polymorphism (SNP) marker rs2603751 showed a nominal association with the risk of TD, as well as with the extent of TD based on the Abnormal Involuntary Movements Scale (AIMS) scores. The haplotype generated by the markers rs2603751 and rs2701124 also showed association with TD and, after adjustment for multiple testing, both the NR4A1 marker rs2603751 and the haplotype continued to show a trend toward association with TD. Although the results of this study are limited by a small sample size, it presents important pilot data and warrants further investigation of the involvement of NR4A1 variants in TD.


Subject(s)
Dyskinesia, Drug-Induced/genetics , Nuclear Receptor Subfamily 4, Group A, Member 1/genetics , Polymorphism, Single Nucleotide/genetics , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Female , Genetic Association Studies , Genotype , Haplotypes/genetics , Humans , Linkage Disequilibrium/genetics , Male , Risk Factors , Schizophrenia/drug therapy , Schizophrenia/genetics
14.
World J Biol Psychiatry ; 10(4 Pt 3): 929-35, 2009.
Article in English | MEDLINE | ID: mdl-19658047

ABSTRACT

Whole genome scan studies have recently identified the NRXN1 and NRXN3 genes as potential contributing factors in the risk for nicotine addiction. We have genotyped 15 single nucleotide polymorphisms (SNPs) spanning the NRXN1 and NRXN3 genes in 195 unrelated patients with schizophrenia for whom information about their smoking status and number of cigarettes smoked per day (CPD) was obtained. The NRXN3 marker rs1004212 was significantly associated with quantity of tobacco smoked. Individuals homozygous for the C allele of rs1004212 smoked more cigarettes per day than heterozygous individuals. We found no significant association of markers within the NRXN1 gene with the risk of smoking or the quantity of tobacco smoked. Because of the relatively small sample size, this is a preliminary study. However, this candidate gene study supports the observations of molecular studies implicating the NRXN genes in drug addiction and suggests that variants in the NRXN3 gene could contribute to the degree of nicotine dependence in patients with schizophrenia.


Subject(s)
Gene Expression/genetics , Nerve Tissue Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Schizophrenia/epidemiology , Schizophrenia/genetics , Smoking/epidemiology , Smoking/genetics , Alleles , Calcium-Binding Proteins , Cell Adhesion Molecules, Neuronal , Codon , Diagnostic and Statistical Manual of Mental Disorders , Disks Large Homolog 4 Protein , Genetic Linkage/genetics , Genetic Variation/genetics , Genotype , Humans , Intracellular Signaling Peptides and Proteins/genetics , Membrane Proteins/genetics , Neural Cell Adhesion Molecules , Risk Factors , Schizophrenia/diagnosis , Tobacco Use Disorder/epidemiology , Tobacco Use Disorder/genetics
15.
Synapse ; 61(10): 827-34, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17603807

ABSTRACT

Recent studies have shown that the elevation in calcium/calmodulin-dependent protein kinase II (CaMKII) may play an important role in amphetamine-induced dopamine release, as well as in the increase of dopamine D2 receptor high-affinitystates in psychosis. Because amphetamine sensitization is a widely used animal model of psychosis or schizophrenia, we investigated whether amphetamine sensitization results in an overall increase in the alpha and beta subunits of CaMKII. To answer this question, we measured CaMKII alpha and beta subunit mRNA expression using Real-Time Quantitative PCR in amphetamine-sensitized rat striata, compared to saline-treated controls. The results were then standardized to beta-glucuronidase, a housekeeping gene. Our results showed a statistically significant increase in the CaMKII beta subunit, and an increase in the alpha subunit which did not reach statistical significance. Because the levels of both CaMKIIbeta and CaMKIIalpha play a role in neuronal function and synapse formation, the present finding of an elevated level of CaMKII beta and alpha subunit mRNA in the amphetamine-sensitized model of psychosis points to the possibility of dysregulated levels of CaMKII subunits in human psychosis.


Subject(s)
Amphetamine/administration & dosage , Calcium-Calmodulin-Dependent Protein Kinases/genetics , Central Nervous System Stimulants/administration & dosage , RNA, Messenger/metabolism , Up-Regulation/drug effects , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 2 , Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Corpus Striatum/drug effects , Corpus Striatum/metabolism , Glucuronidase/genetics , Glucuronidase/metabolism , Male , Protein Subunits/genetics , Protein Subunits/metabolism , Rats , Rats, Sprague-Dawley , Reverse Transcriptase Polymerase Chain Reaction/methods
16.
Brain Res ; 1120(1): 161-71, 2006 Nov 20.
Article in English | MEDLINE | ID: mdl-17022955

ABSTRACT

Schizophrenia may result from altered gene expression leading to abnormal neurodevelopment. In a search for genes with altered expression in schizophrenia, our previous work on human frontal cerebral cortex found the mRNA of Nogo, a myelin-associated protein which inhibits the outgrowth of neurites and nerve terminals, to be overexpressed in schizophrenia. Because those earlier results did not examine tissues for the separate Nogo A, B and C isoforms from age- and sex-matched individuals, we repeated the study for all three isoforms, using a new set of tissues from matched individuals, and using the more accurate method of quantitative real-time PCR (polymerase chain reaction). We found Nogo C to be overexpressed by 26% in the schizophrenia tissues, which is in accordance with our earlier results. The expression of Nogo B was statistically significantly reduced by 17% in the frontal cortices from individuals who had been diagnosed as having had severe depression. Furthermore, we show that there is a direct correlation between the expression of Nogo A and C and the presence of alleles with a CAA insert, irrespective of disease status. While upregulation of Nogo C expression may play a role in schizophrenia, altered Nogo B may contribute to the clinical condition of depression. Nogo A showed a statistically non-significant increase in expression in schizophrenia.


Subject(s)
Bipolar Disorder , Depression , Frontal Lobe/metabolism , Myelin Proteins/metabolism , Polymorphism, Genetic/genetics , Schizophrenia , 3' Untranslated Regions , Adult , Bipolar Disorder/genetics , Bipolar Disorder/pathology , Bipolar Disorder/physiopathology , DNA, Complementary , Depression/genetics , Depression/pathology , Depression/physiopathology , Female , Gene Expression/physiology , Gene Frequency , Genetic Predisposition to Disease , Humans , Male , Middle Aged , Myelin Proteins/genetics , Nogo Proteins , Postmortem Changes , Protein Isoforms , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction/methods , Schizophrenia/genetics , Schizophrenia/pathology , Schizophrenia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...